8
Oct
2024

Osmopharm S.A.

Exhibitor at CPHI Milan 2024 stand 10C1, Finished Dosage Formulations
About Us

Osmopharm SA is a Swiss pharmaceutical contract manufacturer specialized in the development and production of modified release solid oral form drugs. Osmopharm SA is GMP certified by the Swiss health authority Swissmedic, certificate with European validity thanks to the mutual recognition agreement between EU and Switzerland in accordance with quality and good practices defined by PIC/S (Pharmaceutical Inspection Convention/Co-Operation Scheme). With more than 150 formulations developed, the production capacity reaches 36 tons/month of nonsterile products in solid multi-dose form (control...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CH
  • 2015
    On CPHI since
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 10C1, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • Acetazolamide

    Product Acetazolamide

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes acetazolamide. It belongs to diuretic category. Bulk physical form: Pellets. Final dosage form: caps. Contact us for more information.
  • Allopurinol

    Product Allopurinol

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes allopurinol. It belongs to antiurolytic category. Bulk physical form: Pellets. Final dosage form: caps. Contact us for more information.
  • Alprazolam

    Product Alprazolam

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes alprazolam. It belongs to anxiolytic category. Bulk physical form: Pellets. Final dosage form: caps. Contact us for more information.
  • Ambroxol HCI

    Product Ambroxol HCI

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes ambroxol HCI. It belongs to expectorant category. Bulk physical form: pellets, resinates. Final dosage form: caps/tabs. Contact us for more information.
  • Ambroxol HCI + Doxycicline Hyclate

    Product Ambroxol HCI + Doxycicline Hyclate

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes ambroxol HCI + doxycicline hyclate. It is a pharmaceutical association. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.